Tatsumi Yoshiyuki, Yokoo Mamoru, Senda Hisato, Kakehi Kazuaki
Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Shinomiya, Yamashina-ku, Kyoto-city, Kyoto 607-8042, Japan.
Antimicrob Agents Chemother. 2002 Dec;46(12):3797-801. doi: 10.1128/AAC.46.12.3797-3801.2002.
The therapeutic efficacy of KP-103, a novel topical triazole, in a guinea pig tinea unguium model was investigated. Experimental tinea unguium and tinea pedis were produced by inoculation of Trichophyton mentagrophytes SM-110 between the toes of the hind paw of guinea pigs. One percent solution (0.1 ml) of KP-103, amorolfine, or terbinafine was topically applied to the nails and whole sole of an infected foot once daily for 30 consecutive days, and terbinafine was also orally administered at a daily dose of 40 mg/kg of body weight for 30 consecutive days, starting on day 60 postinfection. The fungal burdens of nails and plantar skin were assessed using a new method, which makes it possible to recover infecting fungi by removing a carryover of the drug remaining in the treated tissues into the culture medium. Topically applied KP-103 inhibited the development of nail collapse, significantly reduced the fungal burden of the nails, and sterilized the infected plantar skin. On the other hand, topical amorolfine and topical or oral terbinafine were ineffective for tinea unguium, although these drugs eradicated or reduced the fungal burden of plantar skin. The in vitro activities of amorolfine and terbinafine against T. mentagrophytes SM-110 were 8- and 32-fold, respectively, decreased by the addition of 5% keratin to Sabouraud dextrose broth medium. In contrast, the activity of KP-103 was not affected by keratin because its keratin affinity is lower than those of the reference drugs, suggesting that KP-103 largely exists in the nails as an active form that was not bound to keratin and diffuses in the nail without being trapped by keratin. The effectiveness of KP-103 against tinea unguium is probably due to its favorable pharmacokinetic properties in the nails together with its potent antifungal activity.
研究了新型外用三唑类药物KP - 103在豚鼠甲癣模型中的治疗效果。通过将须癣毛癣菌SM - 110接种于豚鼠后爪趾间,制备实验性甲癣和足癣。将1%的KP - 103溶液(0.1 ml)、阿莫罗芬或特比萘芬每天一次局部应用于感染足的指甲和整个足底,连续30天,从感染后第60天开始,特比萘芬还以每日40 mg/kg体重的剂量口服给药,连续30天。采用一种新方法评估指甲和足底皮肤的真菌负荷,该方法通过去除处理组织中残留药物带入培养基的影响,能够回收感染真菌。局部应用KP - 103可抑制指甲变形的发展,显著降低指甲的真菌负荷,并使感染的足底皮肤除菌。另一方面,外用阿莫罗芬以及外用或口服特比萘芬对甲癣无效,尽管这些药物可根除或降低足底皮肤的真菌负荷。在沙氏葡萄糖肉汤培养基中添加5%角蛋白后,阿莫罗芬和特比萘芬对须癣毛癣菌SM - 110的体外活性分别降低了8倍和32倍。相比之下,KP - 103的活性不受角蛋白影响。因为其对角蛋白的亲和力低于参比药物,这表明KP - 103在指甲中主要以未与角蛋白结合的活性形式存在,可在指甲中扩散而不被角蛋白捕获。KP - 103对甲癣有效的原因可能是其在指甲中具有良好的药代动力学特性以及强大的抗真菌活性。